<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468323</url>
  </required_header>
  <id_info>
    <org_study_id>Palonosetron01</org_study_id>
    <nct_id>NCT02468323</nct_id>
  </id_info>
  <brief_title>Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia</brief_title>
  <acronym>PONV</acronym>
  <official_title>Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia: Study Single Center, Prospective, Double-blind, Randomized, Placebo Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Base</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Base</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the quality of perioperative antiemesis of palonosetron and
      ondansetron in patients undergoing cesarean section
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative nausea and vomiting (PONV) related to spinal block anesthesia are common events
      and unpleasant for pregnant women. Its incidence can reach 80% in high-risk patients, and
      remains high despite the emergence of new antiemetic drugs.

      Episodes untreated can result in prolonged stay in post-anesthetic care unit (PACU) and
      rehospitalization which can result in significant increase in overall costs of health care.

      The purpose of the prophylaxis of PONV is therefore decrease its incidence, the stress of the
      patient, improve the quality and safety of surgical procedure and reduce hospital costs.

      Antagonists of the 5-hydroxytryptamine 3 subtype receptor have been widely used and effective
      against PONV due to its efficacy and a favorable side-effect profile. Palonosetron is a new
      and potent drug generation5 second-HT antagonist with improved profile that acts longer.
      Recent studies where it was compared to ondansetron and palonosetron in high-risk patients in
      head and neck surgery and laparoscopic surgery is disclosed palonosetron far superior to
      ondansetron especially 2-24 hours after surgery. But there are no studies on caesareans
      comparing the two drugs.

      This prospective, randomized, double-blind, placebo controlled, was designed to evaluate the
      efficacy of palonosetron compared with ondansetron and placebo for the prevention of nausea
      and vomiting in patients undergoing cesarean delivery under spinal anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with nausea and vomiting</measure>
    <time_frame>Within the first 48 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea Scores on the Number Rating Scale</measure>
    <time_frame>Within the first 48 hours after surgery</time_frame>
    <description>Quantify nausea by Number Rating Scale (NRS, ranging from 0 to 10 cm, zero being found when the patient is no nausea and ten, with maximum or un bearable nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea Scores on the Verbal Rating Scale</measure>
    <time_frame>Within the first 48 hours after surgery</time_frame>
    <description>Verbal Rating Scale (VRS), consisting of a list of phrases (no nausea, mild nausea, moderate nausea, intense nausea, maximum nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Newborn</measure>
    <time_frame>delivery</time_frame>
    <description>The resulting Apgar score ranges from zero to 10, measured at first and fifth minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert Scale</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Overall satisfaction with the nausea - vomiting experience in a Likert scale of four points (dissatisfied, neutral, satisfied and very satisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>delivery</time_frame>
    <description>Intraoperative hemodynamic stability analysis through the incidence of tachycardia, hypertension, bradycardia, hypotension and consumed vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Within the first 48 hours after surgery</time_frame>
    <description>Incidence of adverse effects such as nausea, vomiting, pruritus, urinary retention, drowsiness and consumed rescue antiemetics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>PONV</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive regular spinal anesthesia</description>
    <arm_group_label>Ondansetron group</arm_group_label>
    <arm_group_label>Palonosetron group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Palonosetron group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Ondansetron group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists class I or II

          -  Scheduled for cesarean section on Maternal and Child Hospital of Brasilia, Federal
             District, Brazil

        Exclusion Criteria:

          -  patients who had received antiemetics, diabetic, allergic to any study drug,
             corticosteroid use, psychoactive drugs, patients with vomiting in the course of
             gastrointestinal disease, eclampsia, heart disease, smokers, any evidence of fetal
             distress, psychiatric disease or who refused to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabricio T Mendonca, MD, TSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Base do Distrito Federal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Base do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70680250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Chattopadhyay S, Goswami S. Palonosetron Versus Ramosetron Prophylaxis for Control of Postoperative Nausea and Vomiting after Cesarean Delivery under Spinal Anesthesia. J Obstet Gynaecol India. 2015 Feb;65(1):28-33. doi: 10.1007/s13224-014-0612-6. Epub 2014 Oct 7.</citation>
    <PMID>25737619</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Base</investigator_affiliation>
    <investigator_full_name>Fabricio Tavares Mendonca</investigator_full_name>
    <investigator_title>MD, TSA</investigator_title>
  </responsible_party>
  <keyword>PONV</keyword>
  <keyword>Palonosetron</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

